Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart,NovoRapid®,and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual...
Arecor Ltd
Advancing today's therapies to enable healthier lives.
Telephone: +44 (0)1223 426 060
Address :
Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Website: http://www.arecor.com
Membership Type: Corporate 21-50
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
There are no Products & Services to display
AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®.
15-06-2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting.
11-06-2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor will leverage its Arestat™ technology to develop liquid formulations of two proprietary novel products in oncology and a rare genetic orphan...
19-03-2020
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
25-02-2020
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical partner will fund the feasibility study and has an exclusive option to a global royalty bearing licence to the new formulation and Arecor’s associated Intellectual Property.
14-02-2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA next week (20-24 January 2020).
16-01-2020
Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.
09-01-2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.
05-12-2019
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at the sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.
18-11-2019
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
04-11-2019
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organisation funding type 1 diabetes (T1D) research.
22-10-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.
06-08-2019
Arecor Ltd , the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
09-07-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
07-05-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, Arestat(TM), to develop superior treatments for a range of disease areas including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.
03-05-2019
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (CTA) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office...
20-03-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.
11-03-2019
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that it has been awarded a £0.5m grant from Innovate UK to advance its proprietary super-fast-acting prandial insulin product, AT270.
13-02-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available for viewing.
24-01-2019
Pages
There are no events to display
There are no jobs to display
No Blog articles found
